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Abstract: Introduction: Recent studies have demonstrated that the ratio of apolipoproteins B and apolipoprotein
A-I is a better predictor of cardiovascular disease than conventional parameters of dyslipidemia. The purpose of this
study was to determine whether apolipoprotein B/apolipoprotein A-I ratio is related to arterial stiffness in a popula-
tion of treated, hypertensive patients.
Methods: The study group consisted of 657 treated hypertension patients. The pulse wave velocity was determined
by measuring hfPWV and baPWV with a VP-1000 pulse wave unit.
Results: The average age of the study population was 55.9±10.1 years of age (range, 30 to 78) with 398 (60.7%)
being male. The average ApoB level was 79.9±21.2 mg/dL and the average ApoAI level was 138.7±24.0 mg/dL.
The average ApoB/ApoAI ratio was 0.60±0.19. The ApoB/ApoAI ratio was significantly lower in males due to the
lower level of ApoAI. After controlling for age, gender, systolic blood pressure, heart rate, DM, body mass index
(BMI), statins and smoking, ApoB/ApoAI was significantly associated with both hfPWV (R
2
 = 0.505, β = 0.068, P
= 0.020) and baPWV (R
2
 = 0.480, β = 0.074, P = 0.013). Subgroup analysis revealed that the significant association
of ApoB/ApoAI was significant only for the male population. [hfPWV (R
2
 = 0.562, β = 0.108, P = 0.003) and
baPWV (R
2
 = 0.467, β = 0.104, P = 0.008)].
Conclusion: We demonstrated, for the first time, a significant association of ApoB/ApoAI with baPWV and hfPWV
in treated, male hypertension patients, after adjustment for confounding factors and medications.
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1. Introduction
Previous epidemiological studies have demonstrated that
increasing arterial stiffness is associated with development
of systolic hypertension and increased risk of cardiovascu-
lar disease.
1-4
 Recent studies have shown the prognostic
importance of identifying arterial stiffness in treated hyper-
tensive patients.
5,6
 Therefore, identification of risk factors
that are associated with arterial stiffness may be important
in hypertensive patients. Although reduction of blood pres-
sure can reduce arterial stiffness in hypertensive patients,
there are other clinical factors involved in the development
of arterial stiffness as well.
 7
 
Case control studies have demonstrated the significant
association of conventional cardiovascular risk factors such
as diabetes mellitus, hypertension and obesity on aortic
stiffness.
8-11
 Some studies have identified hypercholester-
olemia as being significantly associatied with increasing
arterial stiffness.
10,12 
Recent studies have demonstrated that
apolipoproteins B in atherogenic particles and anti athero-
genic apolipoprotein A-I particles in HDLs are better pre-
dictors of cardiovascular disease than conventional
parameters of dyslipidemia.
13-15 
Because high proportion of
patients with hypertension are associated with profiles of
metabolic syndrome (MetS), that is normal to low LDL
cholesterol with high triglyceride and low HDL cholesterol,
the ratio of atherogenic particles and anti-atherogenic parti-
cles may have a greater predictive value. However, popula-
tion studies regarding the association of apolipoprotein B/
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apolipoprotein A-I ratio with arterial stiffness in hyperten-
sive patients have not been demonstrated. 
Therefore, the purpose of this study was to determine
whether apolipoprotein B/apolipoprotein A-I ratio is related
to arterial stiffness, as determined by heart to femoral PWV
(hfPWV) and brachial to ankle PWV (baPWV), in a popula-
tion of treated, hypertensive patients. 
2. Methods
Study population
Among a total of 859 treated hypertensive patients who
underwent pulse wave velocity examination at Yonsei Car-
diovascular Hospital between January 2004 and April 2005,
we included 657 patients who underwent examination for
Apolipoprotein B and Apolipoprotein A-I. For the purposes
of this study, the study group consisted of subjects who
were enrolled in the Yonsei Cardiovascular Genome center.
The Cardiovascular Genome Center is a Korean govern-
ment sponsored research project the objective of which is to
determine the genetic factors that are associated with the
development of cardiovascular disease in a large, prospec-
tive Korean cohort. Our database contained information
about all the constituents of the MetS, and biochemical risk
factors for CAD. Subjects were asked to refrain from
 
per-
forming strenuous exercise or drinking alcoholic beverages
24 hour before the laboratory test. They were also instructed
to avoid eating or drinking anything except water during the
test. 
We recruited treating hypertensive subjects not only with
diagnosis based on a systolic blood pressure of more than
140 mmHg and/or a diastolic blood pressure of more than
90 mmHg over three different visits prior to taking antihy-
pertensive medication but also with taking medications cur-
rently for at least 3 months. Diabetes mellitus is defined as
patients satisfying at least one of three criteria: 1) taking
anti-diabetic medications, 2) fasting blood glucose level
above 126 mg/dL and 3) random blood sugar above 200
mg/dL. Patients with any of the following conditions were
excluded from participation: valvular heart disease, periph-
eral vascular disease, significant systemic disease, a history
of inflammatory disease and on medication inflammatory,
vasoactive drug, a clinically significant atrioventricular con-
duction disturbance, a history of atrial fibrillation or other
serious arrhythmia, a history of congestive heart failure,
severe hypertension (>210/130 mmHg) and serum creati-
nine greater than 1.4 mg/dL. 
At the time of enrollment, patients underwent a complete
physical examination, a baseline electrocardiogram, and a
laboratory assessment. After resting at least five minutes in
a sitting position, office blood pressure (BP) was measured
using a sphygmomanometer with the appropriate cuff size.
Two measurements were taken at least five minutes apart,
and the mean BP was used for analysis. Blood chemistry
(glucose, BUN, uric acid, total cholesterol, total bilirubin,
alkaline phosphatase, AST, ALT, creatinine, Na, K, Triglyc-
eride, HDL, LDL) and fasting serum insulin were assessed.
The fasting serum insulin level was measured with an
immunoradiometric assay and a gamma counter (Hewlett
Packard, USA). The apolipoprotein B and apolipoprotein A
assay was measured by immunoturbidimetry (Roche Diag-
nostics, Basel, Switzerland) as described previously.
16,17
This study was approved beforehand by the institutional
ethics committee, and the procedures followed were in
accordance with the institutional guidelines. All patients
gave informed consent prior to being enrolled.
Pulse wave velocity measurement 
The pulse wave velocity was determined by measuring
hfPWV and baPWV with a VP-1000 pulse wave unit (Nip-
pon Colin Ltd, Komaki City, Japan) as described previously.
18,19
 After an overnight fast and 5 min rest, PWV was mea-
sured from a supine position. Carotid and femoral artery
pressure waveforms were recorded from multi-element
tonometry sensors at the left carotid and the left femoral
arteries. Brachial and tibial artery pressure waveforms were
measured by an oscillometric method as described previ-
ously.
19
 The electrocardiogram was monitored from elec-
trodes on both wrists. Heart sound S1 and S2 were detected
by a microphone on the left edge of the sternum at the third
intercostal space. The waveform analyzer measures time
intervals between S2 and the notch of the carotid pulse
wave (Thc), and between the carotid and femoral artery
pulse wave (Tcf). The sum of Thc and Tcf gives the time
required for pulse waves to travel from the heart (aortic ori-
fice) to the femoral artery (Thf). The hfPWV was calculated
from the following equation: Lhf/(Thc + Tcf). Lhf is the dis-
tance from the heart to the femoral artery. The baPWV was
calculated from the equation: D1-D2/T. D1 is the distance
between the heart and ankle, D2 is the distance between the
heart and brachium and T is the transit between the right
brachial arterial wave and right tibial arterial wave. The dis-
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tance between the sampling points and Lhf are automati-
cally calculated from the patient height, and were divided
by the time interval for the wave form from each measuring
point.
18-20
The baPWV, a central and peripheral stiffness index, and
hfPWV, a central stiffness index, are being used as arterial
stiffness markers, due to ease of measurement, reproducibil-
ity, and validity in previous studies.
19-21
Statistical analysis
In this study, we categorized all the cases into three
groups according to the level of ApoB/ApoA-I ratio.
Results are expressed as the mean±SD. Comparisons of dis-
crete variables were made using the chi-square method and
independent t test was used for continuous variables. If the
distribution was skewed, a non-parametric test was used.
In the multiple linear regression model, the variables that
showed significant association (P < 0.05) in the simple
univariate linear regression analysis and/or are known to
effect indexes of arterial stiffness (hfPWV, baPWV) were
entered into the model. In model 1, the entire population
was used for analysis. In model 2, patients were divided
according to the gender. Because of collinearity, triglycer-
ide, HDL cholesterol and LDL cholesterol were not entered
into the regression analysis. All statistical analysis was per-
formed with SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
3. Results
Clinical characteristics 
The baseline characteristics of the study population are
shown in table 1. The average age of the study population
was 55.9±10.1 years of age (range, 30 to 78) with 398 (60.7
%) being male. Because this was a tertiary care hospital
recruited population cohort, the study group was a relatively
high risk population with 290 (44.2%) patients having a his-
tory of coronary artery disease and 95(14.5%) patients hav-
ing a history of diabetes mellitus (DM). The average ApoB
level was 79.9±21.2 mg/dL and the average ApoAI level
was 138.7±4.0 mg/dL. The average ApoB/ApoAI ratio was
0.60±0.19. The average hfPWV was 971±182 cm/sec and
the average baPWV was 1462±232 cm/sec. All the patients
were taking at least one class of antihypertensive drugs
(Table 2) and 239 (36.4%) patients were taking statins at the
time of testing. The baseline characterstics differed to some
degree according to gender (Table 3). Males were signifi-
cantly younger than the female population and had a signif-
icantly higher proportion of patients with history of
coronary artery disease. The ApoB/ApoAI ratio was signifi-
cantly lower in males due to the lower level of ApoAI. Sig-
nificantly higher proportion of male patients was taking
statins. 
Multiple linear regression
Multiple linear regression of the entire study group(Table
 
Table 1. Baseline characteristics of the study population
N = 656
Age (years) 55.9 ± 10.1
Male (%) 398(60.7%)
Official BP
SBP (mmHg)
DBP (mmHg)
127 ± 16
78 ± 11
Smoking (%) 309(47.1%)
CAD (%) 290(44.2%)
DM(%) 95(14.5%)
BMI (kg/m
2
) 25.3 ± 3.0
T. chol (mg/dl) 183.7 ± 35.7
TG (mg/dl) 147.1 ± 92.4
HDL (mg/dl) 46.2 ± 14.4
LDL (mg/dl) 108.9 ± 34.1
ApoB(mg/dl) 79.9 ± 21.2
ApoAI(mg/dl) 138.7 ± 24.0
ApoB/AI ratio 0.60 ± 0.19
FBS (mg/dl) 94.7 ± 24.7
hfPWV (cm/sec) 971 ± 182
baPWV cm/sec) 1462 ± 232
Values are presented as n (%) or mean ±; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure;CAD, coronary artery disease;
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; FBS, fasting blood sugar; hfPWV, heart to femo-
ral pulse wave velocity; baPWV, brachial-ankle pulse wave velocity. 
Table 2. Antihypertensive and antihyperlipidemic medication
history
N = 656
ACE inhibitors (%) 115(17.5%)
ARB (%) 232(35.4%)
Beta blockers (%) 347(52.9%)
CCB (%) 381(58.1%)
Diuretics (%) 100(15.2%)
Statins (%) 239(36.4%)
Groups were classified according to tertiles; ACE, angiotensin-con-
verting enzyme; ARB, angiotensin-converting enzyme receptor
blocker; CCB, calcium channel blocker
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4) revealed that, after controlling for age, gender, systolic
blood pressure, heart rate, DM, body mass index (BMI),
statins and smoking, ApoB/ApoAI was significantly associ-
ated with both hfPWV (R
2
 = 0.505, β = 0.068, P = 0.020)
and baPWV. (R
2
 = 0.480, β = 0.074, P = 0.013) Subgroup
analysis(Table 5) revealed that the significant association of
ApoB/ApoAI was significant only for the male population.
[hfPWV(R
2
 = 0.562, β = 0.108, P = 0.003) and baPWV (R
2
= 0.467, β = 0.104, P = 0.008)].
4. Discussion
In this study, we demonstrated a significant association of
ApoB/ApoAI with baPWV and hfPWV in treated, male
hypertension patients, after adjustment for confounding fac-
tors and medications. To our knowledge this is the first pop-
ulation study to demonstrate the significant association of
ApoB/ApoAI in hypertension patients. 
Although some studies have reported significant relation-
ship of dyslidemia with arterial stiffness, the relationship is
inconsistent.
10,12,22,23
 Because high proportion of patients
with hypertension are associated with normal to low LDL
cholesterol with high triglyceride and low HDL cholesterol,
the number of atherogenic particles and the antiatherogenic
particles may have a stronger predictive value for cardio-
vascular disease. The level of LDL cholesterol may not
always reflect the number of atherogenic particles in the cir-
culation. This has been well demonstrated in several epide-
miologic studies.
13-15
 The increase in atherogenic particles
may result in impaired bioavailability of nitric oxide with
subsequent increase in oxidative stress and arterial stiff-
ness.
22,24,25
Studies have shown that ApoB/ApoAI ratio is more
closely related with endothelial dependent vasodilation than
LDL cholesterol.
24,26
 Also, the deposition of atherogenic
lipoproteins in the vessel wall may increase the collagen
and calcium content resulting in increase of arterial stiff-
Table 3. Baseline characteristics of the study population accord-
ing to gender
Male(N=398) Female(N=258) P-value
Age (years) 54.6 ± 10.5 57.8 ± 9.0 < 0.001
Official BP
SBP (mmHg)
DBP (mmHg)
127 ± 16
79 ± 11
127 ± 16
76 ± 10
0.868
< 0.001
Smoking (%) 297(74.6%) 12(4.7%) < 0.001
CAD (%) 220(55.3%) 70(27.1%) < 0.001
DM(%) 64(16.1%) 31(12.0%) 0.148
BMI (kg/m
2
) 25.4 ± 2.7 25.1 ± 3.3 0.220
T. chol (mg/dl) 177.4 ± 33.8 193.3 ± 36.6 < 0.001
TG (mg/dl) 150.1 ± 91.3 142.5 ± 94.2 0.302
HDL (mg/dl) 44.5 ± 11.9 48.9 ± 17.2 < 0.001
LDL (mg/dl) 103.6 ± 31.8 117.0 ± 35.9 < 0.001
ApoB(mg/dl) 79.3 ± 20.7 80.8 ± 21.9 0.364
ApoAI(mg/dl) 134.3 ± 21.9 145.5 ± 25.6 <0.001
ApoB/AI ratio 0.61 ± 0.19 0.58 ± 0.19 0.037
FBS (mg/dl) 96.9 ± 26.2 91.3 ± 22.0 0.004
hfPWV (cm/sec) 984 ± 188 952 ± 171 0.028
baPWV cm/sec) 1444 ± 222 1490 ± 245 0.011
Statins 158(39.7%) 81(31.4%) 0.031
Values are presented as n (%) or mean ±; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure;CAD, coronary artery disease;
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; FBS, fasting blood sugar; hfPWV, heart to femo-
ral pulse wave velocity; baPWV, brachial-ankle pulse wave velocity
Table 4. Multiple linear regression analysis for independent
determinants of increased hfPWV and baPWV 
t
Standardized 
Coefficient
P-value
hfPWV ( R
2
 = 0.505)
Age 19.3 0.564 < 0.001
Systolic BP 17.0 0.499 < 0.001
Male gender 4.02 0.155 <0.001
ApoB/ApoAI ratio 2.33 0.068 0.020
Heart rate 2.17 0.062 0.030
DM 2.12 0.060 0.034
BMI -3.66 -1.06 < 0.001
Statin 0.856 0.025 0.392
Smoking 0.211 0.008 0.833
baPWV (R
2 
= 0.480)
Age 14.7 0.440 < 0.001
Systolic BP 18.4. 0.554 < 0.001
Male gender -1.86 -0.073 0.063
ApoB/ApoAI ratio 2.49 0.074 0.013
Heart rate 6.08 0.178 < 0.001
DM 1.54 0.045 0.124
BMI -3.92 -0.117 < 0.001
Statin 0.31 0.009 0.756
Smoking 1.30 0.051 0.193
Hypertensive and lipid-lowering agents were controlled in this anal-
ysis. 
hfPWV, heart to femoral pulse wave velocity; baPWV, brachial to
ankle pulse wave velocity; BP, mean blood pressure; FBS, fasting
blood sugar; BMI, body mass index 
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ness.
24,27
 
The reason for the significant association of ApoB/ApoAI
ratio in males and the lack of association in females is not
clear at this time. The relatively higher ApoAI level, result-
ing in lower level of ApoB/ApoAI ratio and narrow range of
values (0.15-1.22 in females compared to 0.20-1.64 in
males) may be one of the factors influencing the lack of sig-
nificant association in females. Estrogen is associated with
enhancement of endothelial function with data showing sig-
nificant reduction of central arterial stiffness with hormone
replacement therapy.
28,29
 The effect of estrogen on endothe-
lial function may influence the effects of variables such as
the ApoB/ApoAI ratio which effect arterial stiffness
through modification of endothelial function. However, the
fact that majority of women in this study population were
post-menopausal (84.1% of women with age ≥50 years of
age), may have confounded the analysis. We are limited by
a lack of medical history regarding hormone replacement
therapy in this group of patients. 
Although there are reports that aging has a greater influ-
ence in arterial stiffness in females,
30,31
 this was not the case
in this study which demonstrated a smaller standardized
coefficient in females(Table 5).
Although thatl function atio which effect arterial stiffness
thrureplacement therapy.A potential limitation of our study
is that all the patients in this study were treated hypertension
patients. Therefore, the long-term effect of anti-hyperten-
sive medications on arterial stiffness cannot be ruled out as
a confounding factor. Secondly, 239 (36.4%) patients were
taking statins at the time of examination which may account
for the relatively low value of ApoB/ApoAI ratio in this
study. We tried to correct for this confounding factor by
controlling for statin use in the multiple regression analysis.
Thirdly, because the data was a cross sectional analysis, we
could not assess the long term effects of higher ApoB/
ApoAI ratio on the progression of arterial stiffness. 
Fourthly, because this study was performed in a relatively
high risk hypertension patients, the result cannot yet be gen-
eralized to the entire population. Further studies to demon-
strate the association of ApoB/ApoAI ratio with arterial
stiffness in the general population may be needed. 
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